Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data
Crossref DOI link: https://doi.org/10.1007/s40258-016-0271-0
Published Online: 2016-08-22
Published Print: 2017-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Majer, Istvan
van de Wetering, Gijs
Polanyi, Zoltan
Krishna, Arun
Gray, Elisabeth
Roy, Anuja
Funding for this research was provided by:
Novartis Healthcare Pvt. Ltd.
License valid from 2016-08-22